305 related articles for article (PubMed ID: 9615783)
21. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
22. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T
Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938
[TBL] [Abstract][Full Text] [Related]
24. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
25. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice.
Bouvard V; Zaitchouk T; Vacher M; Duthu A; Canivet M; Choisy-Rossi C; Nieruchalski M; May E
Oncogene; 2000 Feb; 19(5):649-60. PubMed ID: 10698510
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas.
Kanavaros P; Stefanaki K; Vlachonikolis J; Eliopoulos G; Kakolyris S; Rontogianni D; Gorgoulis V; Georgoulias V
Histol Histopathol; 2000 Apr; 15(2):445-53. PubMed ID: 10809363
[TBL] [Abstract][Full Text] [Related]
27. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
29. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
Ng IO; Lam KY; Ng M; Regezi JA
Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
[TBL] [Abstract][Full Text] [Related]
30. p53, WAF1/CIP1 and mdm2 expression in skin lesions associated with human papillomavirus and human immunodeficiency virus.
Arany I; Yen A; Tyring SK
Anticancer Res; 1997; 17(2B):1281-5. PubMed ID: 9137486
[TBL] [Abstract][Full Text] [Related]
31. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer.
Veloso M; Wrba F; Kaserer K; Heinze G; Magalhães A; Herbst F; Teleky B
Virchows Arch; 2000 Sep; 437(3):241-7. PubMed ID: 11037343
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
[TBL] [Abstract][Full Text] [Related]
33. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
34. p53, MDM2, bcl-2 staining in follicular neoplasms of the thyroid gland.
Czyz W; Kuzdak K; Pasieka Z; Timler D; Brzeziński J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():167-8. PubMed ID: 11820589
[TBL] [Abstract][Full Text] [Related]
35. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
37. p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years.
Regezi JA; Dekker NP; McMillan A; Ramirez-Amador V; Meneses-Garcia A; Ruiz-Godoy Rivera LM; Chrysomali E; Ng IO
Oral Oncol; 1999 Jul; 35(4):379-83. PubMed ID: 10645402
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
39. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression.
Adachi J; Ookawa K; Kohno T; Tomizawa Y; Tsuchida S; Yokota J
Cell Death Differ; 1998 Feb; 5(2):148-55. PubMed ID: 10200459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
